Western blot imaging aids research in major Spanish hospital

A Syngene multi-application imager is being utilised by scientists at a major hospital in Spain to accelerate Western blot analysis of proteins expressed by white blood cells post-vaccination. Researchers are using the system to analyse rapidly and accurately ECL-labelled chemiluminescent Western blots of cellular receptors and proteins expressed by neutrophils and leucocytes. This fundamental research is allowing the scientists to detect changes in protein expression post-vaccination and is providing information to make predictions about the efficacy of, and potential adverse events associated with, clinical vaccines.

The Syngene system is also fitted with an ultraviolet (UV) transilluminator and green, blue and infrared (IR) light-emitting diode (LED) lighting as the researchers also currently use the system to visualise ethidium bromide-stained DNA gels and may in future image and analyse fluorescent multiplex Western blots.

“We’re delighted to hear that our imaging system is being used to speed up vital research at a major Spanish hospital,” stated Dr Martin Biggs (Sales Manager, Syngene). “Their work is a great endorsement of how this innovative imaging technology can be used in an immunology laboratory to improve the throughput and quality of vaccine testing.”


Other news

Upcoming Events

World Congress of the International Federation of Biomedical Laboratory Science (IFBLS)

Palazza dei Congressi of Firenze
22-26 September 2018

Infection Prevention 2018

Scottish Events Campus, Glasgow
30 September - 2 October 2018

Going Overboard with Microbiology - Women and Children First

Merseyside Maritime Museum, Albert Dock, Liverpool
19 October 2018

Lab Innovations 2018

NEC, Birmingham
31 October - 1 November 2018

Latest Issue

Pathology In Practice

Pathology In Practice

Aug 2018

Cryotomy in a Mohs service: the Welsh experience

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.